Table 1.

Serologic status of 632 paired (pre- and postdeployment) serum samples from Mongolian peacekeepers deploying in a United Nations Peacekeeping mission to South Sudan tested for IgG, hemagglutination-inhibiting or neutralizing antibody specific for various causes of acute febrile illness

	Predeployment seropositive (average titer of positives, if applicable)	Seroconversion (average titer of positives, if applicable)
Typhus group Rickettsia commercial IFA	130 (117.2)	25 (133.1)
SF group Rickettsia commercial IFA*	50 (121.6)	9 (128)
WNV commercial IFA	14 (307.7)	23 (413)
Q fever commercial ELISA	66	12
Leptospirosis commercial ELISA	15	6
DENV-1, HAI/PRNT	3 (16.7)/0	7 (26.7)/0
DENV-2, HAI/PRNT	6 (13.3)/0	7 (26.7)/3 (73.5)
DENV-3, HAI/PRNT	15 (18)/0	13 (41.7)/5 (92.2)
DENV-4, HAI/PRNT	15 (16)/0	14 (45.7)/0
JEV, HAI/PRNT	14 (42.9)/0	20 (108.4)/0

DENV = dengue virus; ELISA = enzyme-linked immunosorbent assay; HAI = hemagglutination inhibition (screening assay); IFA = immunofluorescent antibody assay; JEV = Japanese encephalitis virus; PRNT = plaque-reduction neutralization test (definitive assay); SF = spotted fever. HAI is a screening assay only and not considered to represent definitive evidence of serologic status. The number in the “predeployment seropositive” column for HAI assays represents all samples that had a measurable HAI titer. The number in the “seroconversion” column for HAI assays are those that showed a 4-fold or greater rise in titer. Samples shown as having an HAI 4-fold rise in titer represent 22 samples; many samples had an apparent rise in titer to various combinations of multiple DENV serotypes as well as JEV. Although positive results for PRNT for DENV were obtained with individual serotypes, there was evidence of DENV serotype-to-serotype cross-reactivity, and the results do not necessarily indicate evidence of exposure to a particular DENV serotype.

^*Very rarely separate cases, nearly always positive for typhus group when positive for SF group.